The fund's shares will change in value, and you could lose money by investing in the fund.
Biotechnology and pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services.
Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit.
Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings. First Trust Advisors L. The fund is not sponsored or endorsed by NYSE. NYSE makes no representation or warranty, express or implied, to the owners of the fund or any member of the public regarding the advisability of investing in the fund or the ability of the fund to track the performance of the various sectors represented in the stock market.
NYSE has no obligation to take the needs of the owners of the fund into consideration in determining, composing or calculating the index. NYSE is not responsible for and has not participated in any determination or calculation made with respect to issuance or redemption of the fund. Unit Trusts Search Available Portfolios. Available Closed End Funds. There can be no assurance that the Fund's investment objectives will be achieved.
The NYSE Arca Biotechnology Index SM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Expenses are capped contractually at 0. Holding Percent Exelixis, Inc. Past performance is not indicative of future results.
Alpha is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark. Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure of excess reward per unit of volatility.
Correlation is a measure of the similarity of performance. Risk Considerations The fund's shares will change in value, and you could lose money by investing in the fund. The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person.
First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients. Request a k Proposal Managed Accounts. Since Fund Inception 4. The NAV represents the fund's net assets assets less liabilities divided by the fund's outstanding shares.
Show more Companies link Companies. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance. Actions Add to watchlist Add to portfolio Add an alert.
Add to Your Watchlists New watchlist. Add to Your Portfolio New portfolio. Trailing total returns Daily. Trailing returns analysis 3M. Intra-day ETF pricing data provided by. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.